{"id":14280,"date":"2026-09-10T08:07:29","date_gmt":"2026-09-10T12:07:29","guid":{"rendered":"https:\/\/www.curingheartdisease.com\/?p=14280"},"modified":"2026-09-10T08:07:29","modified_gmt":"2026-09-10T12:07:29","slug":"preventing-your-first-heart-attack","status":"publish","type":"post","link":"https:\/\/www.curingheartdisease.com\/pt\/preventing-your-first-heart-attack\/","title":{"rendered":"Preventing your first heart attack"},"content":{"rendered":"

Abstract<\/h3>\n

VESALIUS-CV randomized 12,257 patients with atherosclerosis or high-risk diabetes but no previous myocardial infarction or stroke to evolocumab 140 mg every two weeks or placebo, added to optimized lipid-lowering therapy [1]. Over a median 4.6 years, evolocumab reduced three-point MACE by 25% and four-point MACE by 19%, and reduced first myocardial infarction by 36% [1]. In the prespecified subgroup with diabetes and no known significant atherosclerosis, both primary endpoints fell by 31% [2]. This paper places that result inside the wider primary-prevention evidence base, from WOSCOPS through JUPITER, HOPE-3, EWTOPIA 75 and the Cholesterol Treatment Trialists analyses, and examines the proposition that these trials are acting on a common quantity: the concentration of apolipoprotein B (apoB) particles available for arterial retention, integrated over time. I set out the arithmetic connecting apoB to LDL cholesterol, explain why the two measures diverge and what follows when they do, give context-dependent reference values, and address two practical questions \u2014 whether evolocumab outperforms a statin, and what it adds when a statin is already in place. The defensible conclusion is narrower than the headlines: intensive PCSK9-mediated lowering can prevent first events in selected high-risk patients, but the trial does not establish routine treatment in average-risk primary prevention, does not establish monotherapy effectiveness, and does not validate a quantitative \u201capoB-years\u201d treatment algorithm.<\/p>\n

1. Why This Trial Changes the Question<\/h3>\n

For thirty years the debate about lipid lowering in people who have never had an event has been a debate about thresholds: how high does risk have to be before treatment is worth it? VESALIUS-CV does not settle that question, but it moves it. It was the first cardiovascular outcomes trial to show that adding a PCSK9 inhibitor to optimized lipid-lowering therapy reduced major cardiovascular events in high-risk patients without prior myocardial infarction or stroke [1].<\/p>\n

That is a narrower claim than \u201cthe first non-statin to work in primary prevention,\u201d and the narrower claim is the correct one. EWTOPIA 75 had already shown that ezetimibe monotherapy reduced atherosclerotic cardiovascular events in Japanese patients aged 75 and older with LDL-C of at least 140 mg\/dL and no history of coronary disease, although that trial was open-label with dietary counseling as the comparator [18].<\/p>\n

What VESALIUS-CV contributes is not a new mechanism. It is confirmation of an established one in a population where it had not been tested with a PCSK9 inhibitor, at an effect size close to what the statin literature predicts for the same magnitude of LDL-C reduction [1,19].<\/p>\n

2. What VESALIUS-CV Actually Tested<\/h3>\n

The trial enrolled 12,257 patients at 774 sites in 33 countries [1]. Median age was 66 years, 43% were women, 93% were White, and median follow-up was 4.6 years. Entry required an LDL-C of at least 90 mg\/dL, non-HDL-C of at least 120 mg\/dL, or apoB of at least 80 mg\/dL, on at least two weeks of optimized therapy. Baseline median LDL-C was approximately 122 mg\/dL and apoB approximately 102 mg\/dL; approximately 87% were receiving a statin, 68% a high-intensity statin, and about 19% ezetimibe [1].<\/p>\n

The population ranged from patients with established atherosclerosis or prior PCI \u2014 but no previous myocardial infarction or stroke \u2014 to patients with high-risk diabetes and no documented significant atherosclerosis. Two-thirds had documented atherosclerosis (45% coronary, 17% peripheral, 10% cerebrovascular) and 59% had diabetes [1]. Participants in the latter group were classified as having no known significant atherosclerosis; they were not systematically imaged in a way that would establish that plaque was absent [2].<\/p>\n

At 48 weeks, evolocumab reduced LDL-C by roughly 55% (45 vs 109 mg\/dL), non-HDL-C by 47%, and apoB by 44% [1]. Lp(a) fell by about 27% [5].<\/p>\n\n\n\n\n\n\n\n\n
Outcome at 5 years<\/strong><\/td>\nEvolocumab<\/strong><\/td>\nPlacebo<\/strong><\/td>\nEffect<\/strong><\/td>\nAbsolute benefit<\/strong><\/td>\n<\/tr>\n<\/thead>\n
CHD death, MI, or ischemic stroke (3-P MACE)<\/td>\n6.2%<\/td>\n8.0%<\/td>\nHR 0.75 (95% CI 0.65\u20130.86)<\/td>\n1.8%; NNT \u2248 56<\/td>\n<\/tr>\n
3-P MACE + ischemia-driven revascularization (4-P)<\/td>\n13.4%<\/td>\n16.2%<\/td>\nHR 0.81 (95% CI 0.73\u20130.89)<\/td>\n2.8%; NNT \u2248 36<\/td>\n<\/tr>\n
Myocardial infarction<\/td>\n2.7%<\/td>\n4.1%<\/td>\nHR 0.64<\/td>\n1.4%; NNT \u2248 71<\/td>\n<\/tr>\n
All-cause death<\/td>\n7.9%<\/td>\n9.7%<\/td>\nHR 0.80<\/td>\nExploratory<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Table 1. Primary and selected secondary outcomes, VESALIUS-CV [1,6]. Mortality fell outside the hierarchical testing sequence because coronary death did not reach significance ahead of it; the 20% relative reduction is hypothesis-generating rather than confirmatory.<\/em><\/p>\n

2.1 Counting every event, not just the first<\/h3>\n

A prespecified cumulative-events analysis counted recurrent as well as first events [3]. Across follow-up there were 1,654 first four-point MACE events and a further 1,107 subsequent events \u2014 2,761 in total, roughly two-thirds more event burden than a conventional time-to-first-event analysis registers. Evolocumab reduced first events by 19%, subsequent events by about 25%, and total events by 20%, preventing approximately 55 first or subsequent events per 1,000 patients treated for five years. For the three-point composite the total-event reduction was 27% [3].<\/p>\n

This bears on how prevention should be valued. A first infarction is often a transition into a higher-risk state rather than a terminal endpoint, and analyses that stop counting at the first event understate the burden that treatment averts [3].<\/p>\n

2.2 The subgroup without known significant atherosclerosis<\/h3>\n

The clearest primary-prevention signal comes from the prespecified subgroup of 3,655 patients with diabetes and no known significant atherosclerosis \u2014 defined as no prior arterial revascularization, no stenosis of 50% or more, and no coronary artery calcium score of 100 Agatston units or higher [2]. Median age was 65 years and 57% were women. At 48 weeks, LDL-C was 52 mg\/dL with evolocumab versus 111 mg\/dL with placebo.<\/p>\n

    \n
  • Three-point MACE: 5.0% vs 7.1% (HR 0.69; 95% CI 0.52\u20130.91; P = .009). Five-year NNT \u2248 48 [2].<\/li>\n
  • Four-point MACE: 7.6% vs 10.5% (HR 0.69). Five-year NNT \u2248 35 [2].<\/li>\n
  • Cardiovascular death HR 0.68 (95% CI 0.46\u20130.99); all-cause death HR 0.76 (95% CI 0.61\u20130.95). Both exploratory given the hierarchical testing order [2].<\/li>\n
  • Event-curve separation was more apparent after the first year, with 41% (3-P) and 39% (4-P) reductions in the years that followed [2].<\/li>\n<\/ul>\n

    That temporal pattern is consistent with, but does not prove, a slower emergence of benefit when baseline plaque burden is lower. A landmark analysis can describe when curves separate; it cannot establish plaque burden or mechanism. If the interpretation is correct, it carries a practical implication \u2014 that fixed-duration primary-prevention trials are structurally conservative \u2014 but that implication rests on the interpretation, not on the data alone.<\/p>\n

    3. The Primary-Prevention Evidence That Came Before<\/h3>\n

    VESALIUS-CV did not arrive in a vacuum. Several trials had already tested lipid lowering in people without established coronary disease, and the pattern across them is consistent enough to be worth tabulating.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
    Trial (year)<\/strong><\/td>\nPopulation<\/strong><\/td>\nRegimen<\/strong><\/td>\nLDL-C lowering<\/strong><\/td>\nPrimary result<\/strong><\/td>\n<\/tr>\n<\/thead>\n
    WOSCOPS (1995) [11]<\/td>\n6,595 men, LDL-C ~192 mg\/dL, no prior MI<\/td>\nPravastatin 40 mg<\/td>\n26% (~48 mg\/dL)<\/td>\nNonfatal MI or CHD death 7.9% \u2192 5.5%; 31% RRR over 4.9 y<\/td>\n<\/tr>\n
    AFCAPS\/TexCAPS (1998) [13]<\/td>\n6,605 with average lipids, low HDL-C<\/td>\nLovastatin 20\u201340 mg<\/td>\n25%<\/td>\nFirst acute major coronary event RR 0.63 over 5.2 y<\/td>\n<\/tr>\n
    ASCOT-LLA (2003) [14]<\/td>\n10,305 hypertensive with \u22653 risk factors<\/td>\nAtorvastatin 10 mg<\/td>\n~35 mg\/dL<\/td>\nNonfatal MI + fatal CHD HR 0.64; stopped early at 3.3 y<\/td>\n<\/tr>\n
    CARDS (2004) [15]<\/td>\n2,838 with type 2 diabetes, no ASCVD<\/td>\nAtorvastatin 10 mg<\/td>\n~46 mg\/dL<\/td>\nMajor CV events HR 0.63 over 3.9 y<\/td>\n<\/tr>\n
    JUPITER (2008) [16]<\/td>\n17,802 with LDL-C <130, hsCRP \u22652 mg\/L<\/td>\nRosuvastatin 20 mg<\/td>\n108 \u2192 55 mg\/dL<\/td>\nComposite HR 0.56; stopped at 1.9 y median<\/td>\n<\/tr>\n
    HOPE-3 (2016) [17]<\/td>\n12,705 at intermediate risk, unselected lipids<\/td>\nRosuvastatin 10 mg<\/td>\n26.5 mg\/dL<\/td>\nCo-primary HR 0.76 over 5.6 y<\/td>\n<\/tr>\n
    EWTOPIA 75 (2019) [18]<\/td>\n3,796 Japanese adults \u226575 y, LDL-C \u2265140, no CAD<\/td>\nEzetimibe 10 mg monotherapy (open-label)<\/td>\n161 \u2192 120 mg\/dL<\/td>\nComposite ASCVD events HR 0.66 over 5 y<\/td>\n<\/tr>\n
    VESALIUS-CV (2026) [1]<\/td>\n12,257 with atherosclerosis or high-risk diabetes, no prior MI\/stroke<\/td>\nEvolocumab 140 mg q2w added to optimized therapy; ~87% on a statin<\/td>\n~63 mg\/dL<\/td>\n3-P MACE HR 0.75; 4-P HR 0.81 over 4.6 y<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Table 2. Trials of lipid lowering in populations without prior myocardial infarction. Values are approximate and drawn from the primary publications; endpoint definitions differ between trials and are not strictly interchangeable.<\/em><\/p>\n

    Two structural features emerge. First, relative benefit per unit of LDL-C removed is at least as large in primary prevention as in secondary prevention. The Cholesterol Treatment Trialists\u2019 2012 individual-participant meta-analysis of 27 trials reported rate ratios per 1.0 mmol\/L (38.7 mg\/dL) of 0.62 and 0.69 in the two lowest baseline-risk categories \u2014 roughly 38% and 31% reductions \u2014 against 0.79 to 0.81 in the higher-risk categories [9]. Restricted to participants without prior ASCVD, the overall rate ratio was 0.75 versus 0.80 in those with prior ASCVD, and the corresponding reductions in the two lowest risk strata were 39% and 34% [9,38]. One possible interpretation is that earlier lipid lowering acts before advanced plaque develops, although differences between risk strata cannot establish this mechanism.<\/p>\n

    Second, absolute benefit is smaller, because the untreated event rate is smaller. In people with a five-year major-vascular-event risk below 10%, each 1.0 mmol\/L of LDL-C reduction prevented about 11 events per 1,000 treated over five years [9]. The absolute benefit was smaller than in higher-risk or post-event populations because baseline event risk was lower; its precise magnitude depends on the population and the endpoint definition. Every design decision in primary prevention is therefore a decision about how to raise the absolute yield: enrich the population by inflammation (JUPITER) [16], by diabetes (CARDS, and the VESALIUS-CV diabetes stratum) [15,2], by imaging-detected plaque, or \u2014 the option trials cannot test \u2014 by extending the treatment horizon from five years to fifty.<\/p>\n

    4. Standardizing Across Trials: Effect per 38.7 mg\/dL<\/h3>\n

    Trials with different drugs, durations, and endpoints become roughly comparable when their results are expressed per unit of LDL-C lowered. An approximate rate ratio per 1 mmol\/L can be calculated as H raised to the power 1\/D, where H is the observed hazard ratio and D the mean LDL-C difference in mmol\/L, assuming a log-linear exposure-response relationship. This standardization does not eliminate differences in follow-up duration, population risk, background treatment, or endpoint definition, and should be read as an ordering device rather than an adjusted estimate.<\/p>\n

    Applied to VESALIUS-CV, the 63 mg\/dL difference is about 1.63 mmol\/L, so a hazard ratio of 0.75 for three-point MACE corresponds to roughly 0.84 per mmol\/L, and 0.81 for four-point MACE to roughly 0.88 [1]. These values are numerically weaker than the CTT benchmark of 0.75\u20130.80. Differences in follow-up duration, endpoint composition, population characteristics, and background therapy may contribute, but cross-trial comparisons cannot establish the explanation. When the investigators compared observed reductions with those predicted from statin trials on the basis of LDL-C reduction alone, agreement was closer: approximately 35% observed versus 31% predicted for major coronary events, and 27% versus 29% for major vascular events [1].<\/p>\n

    Meta-regression has found broadly similar relative risk reductions per mmol\/L of LDL-C lowering for statins and for established non-statin therapies acting through LDL-receptor upregulation [19]. This supports, but does not prove, a shared lipid-mediated mechanism. The practical reading is that there is no strong evidence of an evolocumab-specific or statin-specific effect beyond the lipoprotein reduction each achieves.<\/p>\n

    5. How ApoB and LDL-C Relate to MACE<\/h3>\n

    5.1 The particle as the unit of exposure<\/h4>\n

    Every low-density lipoprotein, intermediate-density lipoprotein, VLDL remnant, and lipoprotein(a) particle carries one molecule of apolipoprotein B-100. Chylomicrons and their remnants carry apoB-48, which contributes a small fraction of total apoB in the fasting state. Total plasma apoB therefore approximates a count of atherogenic particles, expressed as protein mass [24,33].<\/p>\n

    LDL cholesterol is a different quantity: the mass of cholesterol carried within the LDL fraction. Because cholesterol content per particle varies between individuals, the same LDL-C can correspond to meaningfully different particle counts [26].<\/p>\n

    The mechanistic relevance is that the initiating step in atherogenesis is a particle-level event. Particles cross the endothelium at a rate related to their plasma concentration; in the subendothelial space, interactions between positively charged regions of apoB-100 and negatively charged arterial proteoglycans are central to retention, although retention also varies with particle size, composition, and other particle characteristics [24]. Retained particles are oxidatively modified, taken up by macrophages, and converted into foam cells, initiating the inflammatory sequence that produces a necrotic core and, over time, rupture-prone plaque. The response-to-retention model, formalized in the European Atherosclerosis Society consensus statements, therefore predicts that risk should track particle number closely [22,24].<\/p>\n

    Genetic and observational evidence supports this. In multivariable Mendelian randomization, apoB retained a robust association with coronary disease after conditioning on LDL-C and triglycerides, while the independent association of LDL-C did not persist \u2014 though the authors cautioned that high correlation among lipid traits prevents an exclusive causal attribution to apoB [25]. In genetic analyses comparing LDL-receptor variants with lipoprotein-lipase variants, association with coronary risk tracked the absolute change in apoB regardless of which lipid fraction the variant primarily altered [23]. In statin-treated participants in the Copenhagen General Population Study, apoB and non-HDL-C identified residual myocardial infarction risk that LDL-C did not [27]. And in UK Biobank combined with FOURIER and IMPROVE-IT, apoB carried the risk signal while LDL-C and triglycerides added little once apoB was in the model [28].<\/p>\n

    The reasonable summary is not that LDL-C is wrong. It is that LDL-C may underestimate atherogenic particle burden in clinically important groups, including patients with diabetes, insulin resistance, elevated triglycerides, statin treatment, or very low achieved LDL-C [26,33].<\/p>\n

    5.2 The numbers, side by side<\/h4>\n

    Population-median correspondence between LDL-C and apoB, from 12,688 statin-free NHANES participants, gives the practical translation table [26]:<\/p>\n\n\n\n\n\n\n\n\n
    LDL-C (mg\/dL)<\/strong><\/td>\nMedian apoB (mg\/dL)<\/strong><\/td>\n95% apoB range at that LDL-C<\/strong><\/td>\nInterpretation<\/strong><\/td>\n<\/tr>\n<\/thead>\n
    55<\/td>\n49<\/td>\n\u2014<\/td>\nRatio approaches 1:1 at low LDL-C<\/td>\n<\/tr>\n
    70<\/td>\n60<\/td>\n\u2014<\/td>\nAn LDL-C of 70 corresponds to a population-median apoB near 60, not 80 \u2014 conventional guideline pairings are not percentile-equivalent<\/td>\n<\/tr>\n
    100<\/td>\n80<\/td>\n66\u201399<\/td>\nHalf the population falls between 75 and 86 mg\/dL; the outer 5% span a 33 mg\/dL range<\/td>\n<\/tr>\n
    190<\/td>\n140<\/td>\n\u2014<\/td>\nRatio widens as particles become cholesterol-enriched<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Table 3. Population-median apoB across the LDL-C spectrum (NHANES 2005\u20132016, statin-free adults, Martin-Hopkins LDL-C) [26]. Variability was greatest when LDL-C was estimated by Friedewald, lower with Sampson or Martin-Hopkins, and lowest for non-HDL-C.<\/em><\/p>\n

    Points that follow from this:<\/p>\n

      \n
    • At typical levels, apoB (mg\/dL) is roughly 0.8 \u00d7 LDL-C (mg\/dL); at very low LDL-C the ratio approaches 1.0 [26].<\/li>\n
    • Because each atherogenic particle generally contains one apoB molecule, apoB approximates particle concentration. Using the theoretical molecular-mass conversion, an apoB of 100 mg\/dL corresponds to approximately 1,820\u20131,950 nmol\/L, or on the order of 1.1\u20131.2 \u00d7 10\u00b9\u2078 particles per litre; the range reflects published molecular-mass estimates for apoB-100 of roughly 512\u2013550 kDa. This conversion is approximate and is not ordinarily required for clinical interpretation.<\/li>\n
    • Discordance reflects variation in cholesterol mass per apoB-containing particle and in the distribution of particles among LDL, remnants, and Lp(a). An exact cholesterol-molecules-per-particle value cannot be calculated from routine LDL-C and total apoB measurements alone.<\/li>\n
    • Discordantly high apoB \u2014 more particles than the LDL-C implies \u2014 is associated with elevated triglycerides, diabetes, higher HbA1c, obesity, older age, and statin use [26]. Statins lower LDL-C proportionally more than apoB, so a patient at goal on LDL-C may not be at goal on particle number [33].<\/li>\n<\/ul>\n

      5.3 Why apoB is measured differently<\/h4>\n

      LDL-C is, in most laboratories, not measured directly. It is calculated from total cholesterol, HDL-C, and triglycerides using the Friedewald, Martin-Hopkins, or Sampson equations. Each makes assumptions about VLDL composition that degrade at high triglycerides and at low LDL-C \u2014 the two conditions under which treatment decisions are hardest [26].<\/p>\n

      ApoB is measured directly, by immunoturbidimetric or nephelometric immunoassay, standardized against the WHO\/IFCC SP3-07 reference material. It does not require fasting and is measured directly, avoiding the triglyceride-dependent calculation errors that can affect estimated LDL-C, although apoB assays remain subject to analytical variation \u2014 typically a coefficient of variation on the order of 3\u20135% [33]. The reported value is a protein mass concentration; given the one-apoB-per-particle stoichiometry, it functions as a particle-count surrogate.<\/p>\n

      The trade-offs are incomplete reimbursement, inter-laboratory variation in reference ranges, and limited clinical familiarity with the values. The 2026 ACC\/AHA multisociety dyslipidemia guideline addresses this by recommending apoB selectively rather than universally: to improve risk assessment, to help diagnose specific lipoprotein disorders, and once LDL-C and non-HDL-C goals have been met \u2014 particularly with triglycerides above 200 mg\/dL, in diabetes, or at an achieved LDL-C below 70 mg\/dL [32].<\/p>\n

      6. Reference Values: Thresholds, Not Grades<\/h3>\n

      It is tempting to grade lipid values as good, better, and excellent. That framing conflates three different things: guideline treatment goals, population percentiles, and speculative lifetime targets. The defensible presentation separates goals from the thresholds at which intensification is considered, and treats them as context-dependent rather than universal.<\/p>\n\n\n\n\n\n\n\n
      Risk context<\/strong><\/td>\nLDL-C goal<\/strong><\/td>\nNon-HDL-C goal<\/strong><\/td>\nApoB threshold supporting intensification<\/strong><\/td>\n<\/tr>\n<\/thead>\n
      Borderline or intermediate risk<\/td>\n<100 mg\/dL<\/td>\n<130 mg\/dL<\/td>\n\u226590 mg\/dL<\/td>\n<\/tr>\n
      High risk (FH, multiple risk factors, subclinical atherosclerosis)<\/td>\n<70 mg\/dL<\/td>\n<100 mg\/dL<\/td>\n\u226570 mg\/dL<\/td>\n<\/tr>\n
      Established ASCVD at very high risk<\/td>\n<55 mg\/dL<\/td>\n<85 mg\/dL<\/td>\n\u226560 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

      Table 4. LDL-C and non-HDL-C goals from the 2026 ACC\/AHA multisociety dyslipidemia guideline [32], with apoB thresholds for considering intensification of lipid-lowering therapy from the 2024 National Lipid Association expert consensus [33]. These are context-dependent thresholds, not universal grades. The 2019 ESC\/EAS guideline gives corresponding apoB goals of <100, <80, and <65 mg\/dL for moderate, high, and very-high risk [31]; note from Table 3 that these pairings are not percentile-equivalent to their LDL-C counterparts.<\/em><\/p>\n

      Lp(a) sits outside this structure and should be handled separately. Measure it at least once in a lifetime; a level of 125 nmol\/L or above \u2014 approximately 50 mg\/dL \u2014 is risk-enhancing, and roughly 250 nmol\/L is associated with approximately a twofold higher long-term risk [32]. Mass and molar units are not exactly interchangeable, because apo(a) isoform size varies between individuals.<\/p>\n

      Two calibrations are worth holding alongside the guideline numbers, with care about what they do and do not imply. Cord-blood LDL-C in term newborns is typically reported in the range of roughly 20\u201345 mg\/dL, with meaningful variation between cohorts and assay methods [40]. And in the ARIC cohort, Black carriers of rare PCSK9 nonsense variants had approximately 28% lower LDL-C and 88% lower coronary heart disease risk over 15 years [30]. That Mendelian association reflects lifelong exposure and should not be read as an expected treatment effect from starting a drug in midlife, nor as establishing a universal LDL-C target of 50\u201370 mg\/dL.<\/p>\n

      7. Cumulative ApoB Exposure as a Framework<\/h3>\n

      Cumulative exposure to apoB-containing lipoproteins is a biologically coherent framework for understanding lifetime risk. It is not, however, a prospectively validated clinical unit or risk equation, and established plaque can stabilize or regress under treatment [36]. What follows should be read as a way of organizing the evidence, not as a calculator.<\/p>\n

      Three lines of evidence support the framework. Naturally occurring variants that lower LDL-C by 38.7 mg\/dL from birth are associated with roughly 54.5% lower coronary heart disease risk \u2014 approximately three times the reduction observed in trials of therapy begun in later life [21]. This is an association produced by lifelong genetic exposure, not a direct estimate of the effect of starting medication today. Second, cumulative LDL-C exposure from young adulthood through middle age predicts later coronary events independently of the most recent measurement [29]. Third, in the FOURIER open-label extension, patients originally randomized to evolocumab retained lower event and cardiovascular death rates than those whose treatment began about two years later [8]; this is consistent with benefits of earlier treatment, though extension-phase comparisons cannot prove a fixed, irreversible penalty from delay.<\/p>\n\n\n\n\n\n\n\n\n\n\n
      Scenario (ages 20\u201370)<\/strong><\/td>\nApoB trajectory (mg\/dL)<\/strong><\/td>\nCumulative exposure (mg\/dL\u00b7y)<\/strong><\/td>\nReduction vs untreated<\/strong><\/td>\n<\/tr>\n<\/thead>\n
      Untreated<\/td>\n100 throughout<\/td>\n5,000<\/td>\n\u2014<\/td>\n<\/tr>\n
      Therapy from age 50<\/td>\n100 to age 50, then 60<\/td>\n4,200<\/td>\n16%<\/td>\n<\/tr>\n
      Therapy from age 40<\/td>\n100 to age 40, then 60<\/td>\n3,800<\/td>\n24%<\/td>\n<\/tr>\n
      Therapy from age 30<\/td>\n100 to age 30, then 60<\/td>\n3,400<\/td>\n32%<\/td>\n<\/tr>\n
      Intensive from age 30<\/td>\n100 to age 30, then 40<\/td>\n2,600<\/td>\n48%<\/td>\n<\/tr>\n
      Genetically low lifelong<\/td>\n60 throughout<\/td>\n3,000<\/td>\n40%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

      Table 5. Illustrative cumulative-exposure arithmetic. These are exposure integrals under hypothetical trajectories, not validated risk equations, and they carry no implied event rates. They are included to show the structure of the problem \u2014 that timing and duration enter the exposure calculation as directly as level does.<\/em><\/p>\n

      VESALIUS-CV should be set against that framework qualitatively rather than arithmetically. The trial created substantial separation in both LDL-C and apoB over a median 4.6 years and reduced cardiovascular events [1]. It demonstrates that intensive lowering initiated later in life still produces meaningful benefit. It does not license scaling that treatment effect linearly against a hypothetical fifty-year exposure ledger, and LDL-C-years and apoB-years are not interchangeable units in any case.<\/p>\n

      The framework offers one hypothesis about the delayed curve separation in the diabetes subgroup: when advanced plaque burden is lower, benefit may depend more heavily on preventing further cumulative exposure. The subgroup analysis cannot establish this mechanism.<\/p>\n

      8. Is Evolocumab Better Than a Statin?<\/h3>\n

      The question separates into distinct claims, some of which are settled and some of which are not.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
      Dimension<\/strong><\/td>\nStatin<\/strong><\/td>\nEvolocumab<\/strong><\/td>\n<\/tr>\n<\/thead>\n
      Benefit per 38.7 mg\/dL LDL-C removed<\/td>\nRR ~0.79 per mmol\/L across 27 trials [9]<\/td>\nNo randomized head-to-head comparison; meta-regression finds broadly similar reductions per mmol\/L across LDL-receptor-mediated therapies [19]<\/td>\n<\/tr>\n
      Magnitude achievable<\/td>\n30\u201355% LDL-C reduction; effect plateaus with dose<\/td>\n55\u201360% added to maximal statin [1]; ~57% as monotherapy with diet alone [34]<\/td>\n<\/tr>\n
      ApoB reduction in VESALIUS-CV<\/td>\n\u2014<\/td>\n44% on top of existing therapy [1]<\/td>\n<\/tr>\n
      Lp(a)<\/td>\nNo reduction; may rise slightly<\/td>\n20\u201327% reduction [5]<\/td>\n<\/tr>\n
      New-onset diabetes<\/td>\nSmall excess, concentrated in those already near threshold [37]<\/td>\nNo signal [1]<\/td>\n<\/tr>\n
      Muscle symptoms<\/td>\nFrequently reported during statin treatment and a common reason for discontinuation, although the excess of muscle symptoms pharmacologically attributable to statins is small in blinded trials [39]<\/td>\nTolerated in statin-intolerant patients [35]<\/td>\n<\/tr>\n
      Anti-inflammatory effect<\/td>\nLowers hsCRP substantially<\/td>\nMinimal effect on hsCRP<\/td>\n<\/tr>\n
      Monotherapy outcomes evidence<\/td>\nMultiple primary-prevention trials [11,13\u201317]<\/td>\nNone; VESALIUS-CV non-statin subgroup HR ~0.87\u20130.88 with CI crossing 1, underpowered [1]<\/td>\n<\/tr>\n
      Route, cost, access<\/td>\nOral, generic, inexpensive<\/td>\nInjectable every 2 weeks, expensive, often requires prior authorization<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

      Table 6. Statins and evolocumab across the dimensions on which they differ.<\/em><\/p>\n

      There is no randomized head-to-head evidence that evolocumab produces greater event reduction than a statin for the same apoB reduction. Its practical advantage is the large additional LDL-C and apoB reduction it can achieve when background therapy is insufficient [1,19].<\/p>\n

      Lp(a) is the one axis on which the two classes clearly differ pharmacologically. Elevated Lp(a) supports more intensive overall risk reduction [32]. However, cardiovascular benefit from selectively lowering Lp(a) has not yet been established in an outcomes trial. In the VESALIUS-CV Lp(a) analysis, higher baseline Lp(a) remained associated with higher absolute risk, but no statistically significant treatment interaction demonstrated that the modest Lp(a) reduction mediated the benefit [5].<\/p>\n

      9. What It Adds on Top of a Statin<\/h3>\n

      Statins upregulate hepatic LDL receptors but also increase PCSK9, which directs a fraction of those receptors to degradation. This is one reason statin dose-response curves flatten. Blocking PCSK9 removes that constraint, which is why the reductions are largely additive.<\/p>\n

      VESALIUS-CV quantifies the residual. Its participants were, by conventional standards, treated: approximately 87% on a statin, 68% at high intensity, 19% on ezetimibe. They still had a median LDL-C of 122 mg\/dL and apoB of 102 mg\/dL [1]. Adding evolocumab lowered apoB by 44% and produced a 25% reduction in three-point MACE over 4.6 years, with five-year NNTs of 56 and 36 for the three- and four-point endpoints \u2014 or approximately 55 total events per 1,000 treated once recurrent events are counted [1,3].<\/p>\n

      Across randomized trial populations, cardiovascular benefit remained consistent down to achieved LDL-C levels around 20\u201330 mg\/dL, with no observed offsetting safety signal during the available trial follow-up [20]. What changes as achieved levels fall is chiefly the absolute benefit, since the residual risk available to be reduced is smaller.<\/p>\n

      10. What Primary Prevention Should Look Like Now<\/h3>\n
        \n
      1. Measure the right things. Lp(a) at least once in a lifetime. ApoB when triglycerides exceed 200 mg\/dL, in diabetes or insulin resistance, and when achieved LDL-C is below 70 mg\/dL \u2014 the settings in which LDL-C most often underestimates particle burden [32,33].<\/li>\n
      2. Stratify with imaging where it will change management. A coronary calcium score of 100 or more, or a stenosis of 50% or more, placed a VESALIUS-CV participant outside the no-known-atherosclerosis stratum [2]. The 2026 guideline recommends selective rather than universal calcium scoring [32].<\/li>\n
      3. Treat earlier where risk is established. The 2026 guideline frames this as reducing lifelong exposure to atherogenic lipoproteins, with pharmacotherapy considered in young adulthood at LDL-C of 160 mg\/dL or above, or with a strong family history [32].<\/li>\n
      4. Set goals by risk tier and confirm with apoB where indicated: LDL-C below 100 for borderline or intermediate risk, below 70 for high risk, below 55 for very-high-risk established disease [32].<\/li>\n
      5. Escalate according to circumstance. Depending on baseline risk, LDL-C response, statin tolerance, comorbidity, cost, and access, additional therapy may include ezetimibe, bempedoic acid, or a PCSK9-directed agent. VESALIUS-CV supports considering PCSK9 therapy earlier in selected high-risk patients resembling the trial population; it does not establish routine use in all people with diabetes or in average-risk primary prevention [1,2].<\/li>\n
      6. Treat duration as a variable, not a constant. The genetic and cumulative-exposure evidence indicates that when treatment begins matters, not only how far the level falls [21,29] \u2014 while recognizing that this evidence is associational and cannot be converted into a treatment-effect estimate.<\/li>\n<\/ol>\n

        11. Limitations<\/h3>\n
          \n
        • VESALIUS-CV was not a mediation trial. It cannot establish that prevented events were attributable specifically to apoB lowering rather than to correlated effects of the intervention.<\/li>\n
        • The framing of “no prior events” is imprecise. Two-thirds of participants had documented atherosclerosis and 45% had coronary disease; only about a third represented high-risk primary prevention without qualifying atherosclerosis [1,2].<\/li>\n
        • Patients classified as having no known significant atherosclerosis were not systematically imaged to exclude plaque [2].<\/li>\n
        • The diabetes subgroup establishes benefit in high-risk primary prevention. It does not establish benefit in an average-risk person without diabetes, atherosclerosis, or substantially elevated apoB [2].<\/li>\n
        • The trial population was 93% White, limiting generalization [1].<\/li>\n
        • Mortality findings fall outside the hierarchical testing sequence and are exploratory [1,6].<\/li>\n
        • The non-statin subgroup was too small to demonstrate outcome benefit from evolocumab monotherapy; absence of significance in an underpowered subgroup is not evidence of absence [1].<\/li>\n
        • The per-mmol\/L standardization in Section 4 assumes log-linearity and does not adjust for duration, population risk, or endpoint composition.<\/li>\n
        • The cumulative-exposure arithmetic in Table 5 is illustrative. “ApoB-years” is not a validated clinical unit, and LDL-C-years and apoB-years are not interchangeable.<\/li>\n<\/ul>\n

          12. Conclusion<\/h3>\n

          VESALIUS-CV extends intensive lipid lowering upstream of the first major event and shows that the exposure-response relationship governing atherosclerotic risk does not begin at the moment of an infarction [1,2]. Its effect sizes are broadly consistent with what the statin literature predicts for the same reduction in atherogenic lipoproteins, which supports \u2014 without proving \u2014 a shared lipid-mediated mechanism [19].<\/p>\n

          Cumulative exposure to apoB-containing lipoproteins remains the most coherent framework for organizing this evidence, provided it is presented as a framework. LDL-C is a serviceable proxy and the metric on which nearly all outcome evidence rests, but it may underestimate atherogenic particle burden in clinically important groups, including patients with diabetes, insulin resistance, elevated triglycerides, statin treatment, or very low achieved LDL-C. The workable synthesis is to treat LDL-C as the operational target because that is where the trial evidence lives, and to use apoB selectively as a check on whether the LDL-C value is representing particle burden faithfully [32,33].<\/p>\n

          VESALIUS-CV establishes that adding evolocumab to optimized lipid-lowering therapy reduces first major cardiovascular events in selected high-risk patients without prior myocardial infarction or stroke [1]. Most participants with documented atherosclerosis or prior PCI would nevertheless ordinarily be classified as secondary-prevention patients; the 3,655-patient diabetes subgroup without known significant atherosclerosis provides the clearest direct primary-prevention evidence [2]. The trial demonstrated a significant 36% reduction in myocardial infarction, whereas the reduction in ischemic stroke was a nonsignificant trend [1]. It does not establish routine evolocumab treatment for average-risk primary prevention, effectiveness as monotherapy, or a validated cumulative-exposure treatment algorithm.<\/p>\n

          References<\/h3>\n
            \n
          1. Bohula EA, Marston NA, Bhatia AK, et al; VESALIUS-CV Investigators. Evolocumab in patients without a previous myocardial infarction or stroke. N Engl J Med. 2026;394(2):117\u2013127. doi:10.1056\/NEJMoa2514428<\/li>\n
          2. Marston NA, Bohula EA, Bhatia AK, et al; VESALIUS-CV Investigators. Evolocumab to reduce first major cardiovascular events in patients without known significant atherosclerosis and with diabetes: results from the VESALIUS-CV trial. JAMA. 2026;335(16):1400\u20131407. doi:10.1001\/jama.2026.3277<\/li>\n
          3. Nicolau JC, Murphy SA, Giugliano RP, et al. Cumulative benefit with evolocumab in patients with no prior myocardial infarction or stroke in the VESALIUS-CV study. J Am Coll Cardiol. 2026 Aug 28:S0735-1097(26)07440-1. doi:10.1016\/j.jacc.2026.08.015. PMID: 42663360<\/li>\n
          4. Bergmark BA, Bohula EA, Marston NA, et al. Evolocumab in patients with prior percutaneous coronary intervention and no prior MI: results from the VESALIUS-CV trial. Circulation. 2026;154(1):28\u201336. doi:10.1161\/CIRCULATIONAHA.126.080616<\/li>\n
          5. Monguillon V, Marston NA, Bohula EA, et al. Lipoprotein(a) levels, risk of cardiovascular events, and benefit of evolocumab: findings from the VESALIUS-CV trial. Circulation. 2026;153(25):1960\u20131968. doi:10.1161\/CIRCULATIONAHA.126.080999<\/li>\n
          6. Giugliano RP, Bohula EA, Bellavia A, et al. Effects of evolocumab on mortality outcomes in patients without previous myocardial infarction or stroke: a prespecified analysis of the VESALIUS-CV randomized clinical trial. Circulation. 2026. doi:10.1161\/CIRCULATIONAHA.126.082436<\/li>\n
          7. Sabatine MS, Giugliano RP, Keech AC, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u20131722.<\/li>\n
          8. O\u2019Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease (FOURIER-OLE). Circulation. 2022;146(15):1109\u20131119.<\/li>\n
          9. Cholesterol Treatment Trialists\u2019 (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581\u2013590.<\/li>\n
          10. Cholesterol Treatment Trialists\u2019 (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u20131681.<\/li>\n
          11. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia (WOSCOPS). N Engl J Med. 1995;333(20):1301\u20131307.<\/li>\n
          12. Ford I, Murray H, McCowan C, Packard CJ. Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of the West of Scotland Coronary Prevention Study. Circulation. 2016;133(11):1073\u20131080.<\/li>\n
          13. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: AFCAPS\/TexCAPS. JAMA. 1998;279(20):1615\u20131622.<\/li>\n
          14. Sever PS, Dahl\u00f6f B, Poulter NR, et al; ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations (ASCOT-LLA). Lancet. 2003;361(9364):1149\u20131158.<\/li>\n
          15. Colhoun HM, Betteridge DJ, Durrington PN, et al; CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes (CARDS). Lancet. 2004;364(9435):685\u2013696.<\/li>\n
          16. Ridker PM, Danielson E, Fonseca FAH, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195\u20132207.<\/li>\n
          17. Yusuf S, Bosch J, Dagenais G, et al; HOPE-3 Investigators. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374(21):2021\u20132031.<\/li>\n
          18. Ouchi Y, Sasaki J, Arai H, et al. Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75): a randomized, controlled trial. Circulation. 2019;140(12):992\u20131003. doi:10.1161\/CIRCULATIONAHA.118.039415<\/li>\n
          19. Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316(12):1289\u20131297.<\/li>\n
          20. Sabatine MS, Wiviott SD, Im K, Murphy SA, Giugliano RP. Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels: a meta-analysis. JAMA Cardiol. 2018;3(9):823\u2013828.<\/li>\n
          21. Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):2631\u20132639.<\/li>\n
          22. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u20132472.<\/li>\n
          23. Ference BA, Kastelein JJP, Ray KK, et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA. 2019;321(4):364\u2013373.<\/li>\n
          24. Bor\u00e9n J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):2313\u20132330.<\/li>\n
          25. Richardson TG, Sanderson E, Palmer TM, et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis. PLoS Med. 2020;17(3):e1003062.<\/li>\n
          26. Sayed A, Peterson ED, Virani SS, et al. Individual variation in the distribution of apolipoprotein B levels across the spectrum of LDL-C or non-HDL-C levels. JAMA Cardiol. 2024;9(8):741\u2013747. doi:10.1001\/jamacardio.2024.1310<\/li>\n
          27. Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients. J Am Coll Cardiol. 2021;77(11):1439\u20131450.<\/li>\n
          28. Marston NA, Giugliano RP, Melloni GEM, et al. Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis. JAMA Cardiol. 2022;7(3):250\u2013256.<\/li>\n
          29. Zhang Y, Pletcher MJ, Vittinghoff E, et al. Association between cumulative low-density lipoprotein cholesterol exposure during young adulthood and middle age and risk of cardiovascular events. JAMA Cardiol. 2021;6(12):1406\u20131413.<\/li>\n
          30. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264\u20131272.<\/li>\n
          31. Mach F, Baigent C, Catapano AL, et al; ESC Scientific Document Group. 2019 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111\u2013188.<\/li>\n
          32. 2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026. doi:10.1161\/CIR.0000000000001423<\/li>\n
          33. Soffer DE, Marston NA, Maki KC, et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an expert clinical consensus from the National Lipid Association. J Clin Lipidol. 2024;18(5):e647\u2013e663. doi:10.1016\/j.jacl.2024.08.013<\/li>\n
          34. Blom DJ, Hala T, Bolognese M, et al; DESCARTES Investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370(19):1809\u20131819.<\/li>\n
          35. Nissen SE, Stroes E, Dent-Acosta RE, et al; GAUSS-3 Investigators. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance. JAMA. 2016;315(15):1580\u20131590.<\/li>\n
          36. Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316(22):2373\u20132384.<\/li>\n
          37. Cholesterol Treatment Trialists\u2019 Collaboration. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia: individual participant meta-analysis. Lancet Diabetes Endocrinol. 2024;12(5):306\u2013319.<\/li>\n
          38. Kalra DK, Ray KK, Bajaj A, et al. Low-density lipoprotein cholesterol lowering and risk of major adverse cardiovascular events in primary prevention trials: a meta-analysis. J Clin Lipidol. 2026;20(4):738\u2013749. doi:10.1016\/j.jacl.2026.02.006<\/li>\n
          39. Cholesterol Treatment Trialists\u2019 Collaboration. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet. 2022;400(10355):832\u2013845. doi:10.1016\/S0140-6736(22)01545-8<\/li>\n
          40. Fetal and neonatal cholesterol metabolism. In: Feingold KR, Ahmed SF, Blackman MR, et al., eds. Endotext. South Dartmouth, MA: MDText.com, Inc.; updated 2023. NCBI Bookshelf NBK395580.<\/li>\n<\/ol>\n

            This paper is educational content prepared for curingheartdisease.com and is not medical advice. Treatment decisions should be made with a qualified clinician.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

            Can lowering cholesterol particles prevent your first heart attack? Learn how the VESALIUS-CV trial and ApoB particle counts are changing primary prevention.<\/p>","protected":false},"author":16,"featured_media":14288,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[219,220,223,224],"tags":[],"class_list":["post-14280","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-lipids-medications-and-testing","category-medications-and-treatments","category-plaque-arteries-and-disease","category-regression-and-reversal"],"acf":[],"yoast_head":"\nPreventing your first heart attack - The Premiere Heart Health Education Platform<\/title>\n<meta name=\"description\" content=\"Can lowering cholesterol particles prevent your first heart attack? Learn how the VESALIUS-CV trial and ApoB particle counts are changing primary prevention.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.curingheartdisease.com\/pt\/preventing-your-first-heart-attack\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Preventing your first heart attack - The Premiere Heart Health Education Platform\" \/>\n<meta property=\"og:description\" content=\"Can lowering cholesterol particles prevent your first heart attack? Learn how the VESALIUS-CV trial and ApoB particle counts are changing primary prevention.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.curingheartdisease.com\/pt\/preventing-your-first-heart-attack\/\" \/>\n<meta property=\"og:site_name\" content=\"The Premiere Heart Health Education Platform\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/curingheartdisease\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-10T12:07:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/09\/post-image-99.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Peter Megdal PhD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@RMHDInc\" \/>\n<meta name=\"twitter:site\" content=\"@RMHDInc\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Peter Megdal PhD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"26 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/preventing-your-first-heart-attack\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/preventing-your-first-heart-attack\\\/\"},\"author\":{\"name\":\"Peter Megdal PhD\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\"},\"headline\":\"Preventing your first heart attack\",\"datePublished\":\"2026-09-10T12:07:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/preventing-your-first-heart-attack\\\/\"},\"wordCount\":5438,\"publisher\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/preventing-your-first-heart-attack\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/post-image-99.jpg\",\"articleSection\":[\"Lipids, Medications and Testing\",\"Medications and Treatments\",\"Plaque, Arteries and Disease\",\"Regression and Reversal\"],\"inLanguage\":\"pt-BR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/preventing-your-first-heart-attack\\\/\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/preventing-your-first-heart-attack\\\/\",\"name\":\"Preventing your first heart attack - The Premiere Heart Health Education Platform\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/preventing-your-first-heart-attack\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/preventing-your-first-heart-attack\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/post-image-99.jpg\",\"datePublished\":\"2026-09-10T12:07:29+00:00\",\"description\":\"Can lowering cholesterol particles prevent your first heart attack? Learn how the VESALIUS-CV trial and ApoB particle counts are changing primary prevention.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/preventing-your-first-heart-attack\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.curingheartdisease.com\\\/preventing-your-first-heart-attack\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/preventing-your-first-heart-attack\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/post-image-99.jpg\",\"contentUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/post-image-99.jpg\",\"width\":1200,\"height\":630},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/preventing-your-first-heart-attack\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.curingheartdisease.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Preventing your first heart attack\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#website\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/\",\"name\":\"The Premiere Heart Health Education Platform\",\"description\":\"To make available to the public the state of the art information on how to reverse heart disease. This is an evidence-based organization utilizing the best available science, including diet, exercise drugs, and other resources to best fight this disease.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.curingheartdisease.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\",\"name\":\"Curing Heart Disease, LLC\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/cropped-Curing-Heart-icon-red.png\",\"contentUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/cropped-Curing-Heart-icon-red.png\",\"width\":512,\"height\":512,\"caption\":\"Curing Heart Disease, LLC\"},\"image\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/curingheartdisease\",\"https:\\\/\\\/x.com\\\/RMHDInc\",\"https:\\\/\\\/www.instagram.com\\\/rmhdinc\\\/\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCm8dh9c_D5RfJL7Z1f-yY4w\"],\"description\":\"Curing Heart Disease, LLC is an independent cardiovascular health education organization that publishes evidence-based articles, videos, podcasts, and educational tools about cardiovascular disease prevention, lipid science, nutrition, exercise, and related health topics.\",\"founder\":{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\",\"name\":\"Peter Megdal, PhD\"},\"foundingPerson\":{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\",\"name\":\"Peter Megdal, PhD\"},\"knowsAbout\":[\"Cardiovascular health\",\"Cardiovascular disease prevention\",\"Heart disease education\",\"Nutrition\",\"Exercise\",\"Lipid science\",\"Atherosclerosis\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\",\"name\":\"Peter Megdal, PhD\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/peters-story\\\/\",\"givenName\":\"Peter\",\"familyName\":\"Megdal\",\"honorificSuffix\":\"PhD\",\"jobTitle\":\"Nutrition Researcher and Cardiovascular Health Educator\",\"description\":\"Peter Megdal, PhD, is a nutrition researcher, cardiovascular health educator, published researcher, and longtime competitive cyclist. He earned a PhD in nutrition from the University of Massachusetts and publishes evidence-based cardiovascular health education through Curing Heart Disease.\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/peters-story\\\/\"},\"worksFor\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"affiliation\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"alumniOf\":{\"@type\":\"CollegeOrUniversity\",\"name\":\"University of Massachusetts\"},\"knowsAbout\":[\"Nutrition\",\"Cardiovascular health education\",\"Cardiovascular disease prevention\",\"Lipid science\",\"Exercise physiology\",\"Scientific research\"],\"sameAs\":[\"https:\\\/\\\/www.curingheartdisease.com\\\/author\\\/peter-megdal\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/in\\\/peter-megdal-56075a2\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Preventing your first heart attack - The Premiere Heart Health Education Platform","description":"Can lowering cholesterol particles prevent your first heart attack? Learn how the VESALIUS-CV trial and ApoB particle counts are changing primary prevention.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.curingheartdisease.com\/pt\/preventing-your-first-heart-attack\/","og_locale":"pt_BR","og_type":"article","og_title":"Preventing your first heart attack - The Premiere Heart Health Education Platform","og_description":"Can lowering cholesterol particles prevent your first heart attack? Learn how the VESALIUS-CV trial and ApoB particle counts are changing primary prevention.","og_url":"https:\/\/www.curingheartdisease.com\/pt\/preventing-your-first-heart-attack\/","og_site_name":"The Premiere Heart Health Education Platform","article_publisher":"https:\/\/www.facebook.com\/curingheartdisease","article_published_time":"2026-09-10T12:07:29+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/09\/post-image-99.jpg","type":"image\/jpeg"}],"author":"Peter Megdal PhD","twitter_card":"summary_large_image","twitter_creator":"@RMHDInc","twitter_site":"@RMHDInc","twitter_misc":{"Escrito por":"Peter Megdal PhD","Est. tempo de leitura":"26 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.curingheartdisease.com\/preventing-your-first-heart-attack\/#article","isPartOf":{"@id":"https:\/\/www.curingheartdisease.com\/preventing-your-first-heart-attack\/"},"author":{"name":"Peter Megdal PhD","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53"},"headline":"Preventing your first heart attack","datePublished":"2026-09-10T12:07:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.curingheartdisease.com\/preventing-your-first-heart-attack\/"},"wordCount":5438,"publisher":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"image":{"@id":"https:\/\/www.curingheartdisease.com\/preventing-your-first-heart-attack\/#primaryimage"},"thumbnailUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/09\/post-image-99.jpg","articleSection":["Lipids, Medications and Testing","Medications and Treatments","Plaque, Arteries and Disease","Regression and Reversal"],"inLanguage":"pt-BR"},{"@type":"WebPage","@id":"https:\/\/www.curingheartdisease.com\/preventing-your-first-heart-attack\/","url":"https:\/\/www.curingheartdisease.com\/preventing-your-first-heart-attack\/","name":"Preventing your first heart attack - The Premiere Heart Health Education Platform","isPartOf":{"@id":"https:\/\/www.curingheartdisease.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.curingheartdisease.com\/preventing-your-first-heart-attack\/#primaryimage"},"image":{"@id":"https:\/\/www.curingheartdisease.com\/preventing-your-first-heart-attack\/#primaryimage"},"thumbnailUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/09\/post-image-99.jpg","datePublished":"2026-09-10T12:07:29+00:00","description":"Can lowering cholesterol particles prevent your first heart attack? Learn how the VESALIUS-CV trial and ApoB particle counts are changing primary prevention.","breadcrumb":{"@id":"https:\/\/www.curingheartdisease.com\/preventing-your-first-heart-attack\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.curingheartdisease.com\/preventing-your-first-heart-attack\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/www.curingheartdisease.com\/preventing-your-first-heart-attack\/#primaryimage","url":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/09\/post-image-99.jpg","contentUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/09\/post-image-99.jpg","width":1200,"height":630},{"@type":"BreadcrumbList","@id":"https:\/\/www.curingheartdisease.com\/preventing-your-first-heart-attack\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.curingheartdisease.com\/"},{"@type":"ListItem","position":2,"name":"Preventing your first heart attack"}]},{"@type":"WebSite","@id":"https:\/\/www.curingheartdisease.com\/#website","url":"https:\/\/www.curingheartdisease.com\/","name":"A principal plataforma de educa\u00e7\u00e3o sobre a sa\u00fade do cora\u00e7\u00e3o","description":"Disponibilizar ao p\u00fablico informa\u00e7\u00f5es de \u00faltima gera\u00e7\u00e3o sobre como reverter doen\u00e7as card\u00edacas. Trata-se de uma organiza\u00e7\u00e3o baseada em evid\u00eancias que utiliza a melhor ci\u00eancia dispon\u00edvel, incluindo dieta, exerc\u00edcios, medicamentos e outros recursos para combater melhor esta doen\u00e7a.","publisher":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.curingheartdisease.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/www.curingheartdisease.com\/#organization","name":"Curing Heart Disease, LLC","url":"https:\/\/www.curingheartdisease.com\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/06\/cropped-Curing-Heart-icon-red.png","contentUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/06\/cropped-Curing-Heart-icon-red.png","width":512,"height":512,"caption":"Curing Heart Disease, LLC"},"image":{"@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/curingheartdisease","https:\/\/x.com\/RMHDInc","https:\/\/www.instagram.com\/rmhdinc\/","https:\/\/www.youtube.com\/channel\/UCm8dh9c_D5RfJL7Z1f-yY4w"],"description":"Curing Heart Disease, LLC \u00e9 uma organiza\u00e7\u00e3o independente de educa\u00e7\u00e3o em sa\u00fade cardiovascular que publica artigos, v\u00eddeos, podcasts e ferramentas educacionais baseados em evid\u00eancias sobre preven\u00e7\u00e3o de doen\u00e7as cardiovasculares, ci\u00eancia dos lip\u00eddios, nutri\u00e7\u00e3o, exerc\u00edcios e t\u00f3picos de sa\u00fade relacionados.","founder":{"@type":"Person","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53","name":"Peter Megdal, PhD"},"foundingPerson":{"@type":"Person","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53","name":"Peter Megdal, PhD"},"knowsAbout":["Cardiovascular health","Cardiovascular disease prevention","Heart disease education","Nutrition","Exercise","Lipid science","Atherosclerosis"]},{"@type":"Person","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53","name":"Peter Megdal, PhD","url":"https:\/\/www.curingheartdisease.com\/peters-story\/","givenName":"Peter","familyName":"Megdal","honorificSuffix":"PhD","jobTitle":"Nutrition Researcher and Cardiovascular Health Educator","description":"Peter Megdal, PhD \u00e9 pesquisador na \u00e1rea de nutri\u00e7\u00e3o, educador em sa\u00fade cardiovascular, autor de trabalhos cient\u00edficos e ciclista de competi\u00e7\u00e3o de longa data. Ele obteve o t\u00edtulo de doutor em nutri\u00e7\u00e3o pela Universidade de Massachusetts e divulga informa\u00e7\u00f5es sobre sa\u00fade cardiovascular baseadas em evid\u00eancias por meio do site \u201cCuring Heart Disease\u201d.","mainEntityOfPage":{"@id":"https:\/\/www.curingheartdisease.com\/peters-story\/"},"worksFor":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"affiliation":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"alumniOf":{"@type":"CollegeOrUniversity","name":"University of Massachusetts"},"knowsAbout":["Nutrition","Cardiovascular health education","Cardiovascular disease prevention","Lipid science","Exercise physiology","Scientific research"],"sameAs":["https:\/\/www.curingheartdisease.com\/author\/peter-megdal\/","https:\/\/www.linkedin.com\/in\/peter-megdal-56075a2\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.curingheartdisease.com\/pt\/wp-json\/wp\/v2\/posts\/14280","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.curingheartdisease.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.curingheartdisease.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/pt\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/pt\/wp-json\/wp\/v2\/comments?post=14280"}],"version-history":[{"count":5,"href":"https:\/\/www.curingheartdisease.com\/pt\/wp-json\/wp\/v2\/posts\/14280\/revisions"}],"predecessor-version":[{"id":14287,"href":"https:\/\/www.curingheartdisease.com\/pt\/wp-json\/wp\/v2\/posts\/14280\/revisions\/14287"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/pt\/wp-json\/wp\/v2\/media\/14288"}],"wp:attachment":[{"href":"https:\/\/www.curingheartdisease.com\/pt\/wp-json\/wp\/v2\/media?parent=14280"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/pt\/wp-json\/wp\/v2\/categories?post=14280"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/pt\/wp-json\/wp\/v2\/tags?post=14280"}],"curies":[{"name":"bom trabalho","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}